Nav1.7
voltage-gated sodium channel inhibitors are the drug candidates that target the sodium
channels Nav1.7 and have been significant in pain management. The sodium
channels Nav1.7 receptors are generally found in two types of neurons:
nociceptive pain neurons, such as trigeminal neurons and dorsal root ganglion;
and sympathetic ganglion neurons which form a part of the autonomic
(involuntary) nervous system. These receptors play an important role in
generation and conduction of action potential.
The sodium
channels Nav1.7 is generally encoded by SCN9A gene. Voyager Therapeutics Inc.
is developing VY-NAV01 as a Nav1.7-voltage-gated-sodium-channel-inhibitor for
the treatment of severe and chronic pain. Sumitomo Dainippon Pharma Co. Ltd. is
in the process of developing DSP-2230 as a Nav1.7 and Nav1.8
voltage-gated-sodium-channel-inhibitor for the treatment of neuropathic pain.
Some of the companies having the pipeline of Nav1.7 voltage-gated sodium
channel inhibitors include Xenon Pharmaceuticals Incorporated, SiteOne
Therapeutics Inc., Icagen Inc. and others.
Request
to Get the Sample Pages at:
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials. Pipeline analysis of drugs by phases includes
product description and development activities including information about
clinical results, designations, collaborations, licensing, grants, technology,
and others.
No comments:
Post a Comment